Title |
The distinctive nature of adenocarcinoma of the lung
|
---|---|
Published in |
OncoTargets and therapy, September 2015
|
DOI | 10.2147/ott.s89225 |
Pubmed ID | |
Authors |
Giandomenico Roviello |
Abstract |
In recent years, many personalized treatments have been developed for NSCLC (non-small-cell lung cancer) patients. Among these, gefitinib, erlotinib, and afatinib are selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for patients with EGFR gene mutations, while crizotinib and ceritinib are two new tyrosine kinase inhibitors directed against the echinoderm microtubule-like protein 4-anaplastic lymphoma kinase translocation. The possibility of these new molecules being used to treat patients without adenocarcinoma histology is notably small. For example, EGFR mutations and anaplastic lymphoma kinase fusion gene rearrangement are rare in patients with squamous cell carcinoma (generally <1%). Additionally, the benefit of targeted treatment approaches in patients with small-cell lung cancer histology is limited. All of these findings highlight the distinctive nature of adenocarcinoma of the lung among all lung cancer subtypes. Unfortunately, to date, less than 15% of patients with adenocarcinoma of the lung are ideal candidates for these targeted therapies. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Australia | 1 | 20% |
Canada | 1 | 20% |
United States | 1 | 20% |
Unknown | 2 | 40% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 80% |
Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 43 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 9 | 21% |
Student > Ph. D. Student | 6 | 14% |
Student > Master | 5 | 12% |
Student > Doctoral Student | 4 | 9% |
Other | 2 | 5% |
Other | 4 | 9% |
Unknown | 13 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 8 | 19% |
Medicine and Dentistry | 8 | 19% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 12% |
Agricultural and Biological Sciences | 5 | 12% |
Nursing and Health Professions | 1 | 2% |
Other | 2 | 5% |
Unknown | 14 | 33% |